1. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo
   H M Schmetzer et al, 2007, Leukemia CrossRef
2. Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.
   Heleen H Van Acker et al, 2019, J Clin Med CrossRef
3. Can Dendritic Cell Vaccination Prevent Leukemia Relapse?
   Liam J. O’Brien et al, 2019, Cancers CrossRef
4. Cellular immunotherapy for leukemia
   Norimitsu Kadowaki et al, 2013, DDS CrossRef
5. Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.
   Daniel Christoph Amberger et al, 2020, Transfus Med Hemother CrossRef
6. Theory and Practice of Immunotherapy Directed against the PRAME Antigen
   V.A. Misyurin, 2018, Клиническая онкогематология CrossRef
7. Automate platform for Capturing and Counting ELISpot on 96-Well Plate
   Chayatorn Kukiattikoon et al, 2021 CrossRef
8. A Causal Role for the Human Tumor Antigen Preferentially Expressed Antigen of Melanoma in Cancer
   Mirjam T. Epping et al, 2006 CrossRef
9. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck.
   Carmen Visus et al, 2007, Cancer Res. CrossRef
10. Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
    Kordelia Barbullushi et al, 2022, Cancers CrossRef
11. Generation of Leukaemia-Derived Dendritic Cells (DC_leu) to Improve Anti-Leukaemic Activity in AML: Selection of the Most Efficient Response Modifier Combinations.
    Christoph Schwepcke et al, 2022, Int J Mol Sci CrossRef
12. Development of an Automated Viral Plaque Assay Program and ELISpot Counting Program on 96-Well Plate Platform
    Suphanut Plengkham et al, 2022 CrossRef